Search
Chicago, IL Paid Clinical Trials
A listing of 1984 clinical trials in Chicago, IL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
973 - 984 of 1984
There are currently 1984 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Recruiting
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Rush University Cancer Center, Chicago, Illinois
Conditions: Pancreatic Cancer
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
Recruiting
This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care.
The Primary Aim is to determine the comparative effectiveness (as defined by "much" or "very much" better on PGI-I) of transurethral bulking agent (TBA) \[for 1 or 2 injections in 12 months\] vs. single-incision sling (SIS) 12 months after treatment interventio... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/02/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Stress Urinary Incontinence, Urinary Incontinence, Mixed Urinary Incontinence
Technology-Enhanced Asthma Care in Children at Clinic and Home Study
Recruiting
A randomized controlled trial with parent-child pairs of children with persistent or uncontrolled asthma. An intervention group (n=40 parent-child pairs) will receive the mobile health (mHealth) app and digital sensors with enhanced support from a population health manager role, hereinafter referred to as an asthma coordinator, to provide remote patient monitoring (RPM). A comparison group (n=40 parent-child pairs) will receive the mHealth app and sensors without RPM support to silently collect... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
04/02/2025
Locations: Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Asthma in Children, Chronic Diseases in Children
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
Recruiting
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis.
Duration of study period (per participant)
* Screening period: Up to 12 weeks before Week 0
* Randomized double-blind period: 24 weeks
*... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Northwestern University- Site Number : 8400003, Chicago, Illinois
Conditions: Eosinophilic Oesophagitis
Shockwave in Postoperative Breast Reconstruction Fibrosis
Recruiting
This study evaluates the potential for extracorporeal shockwave therapy to reduce post-operative soft tissue fibrosis.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Lavin Pavilion Suite 2060, Chicago, Illinois
Conditions: Fibrosis Breast
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd.
The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Illinois at Chicago (Site 008-012), Chicago, Illinois
Conditions: COVID-19
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Recruiting
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
04/02/2025
Locations: Alkermes Investigator Site, Chicago, Illinois
Conditions: Schizophrenia, Bipolar I Disorder
Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
A Phase 1, Open label, Multiple Ascending Dose Study to Assess Safety and Tolerability of STM-01 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Fostering Optimal Regulation of Emotion for Prevention of Secondary Trauma (FOREST)
Recruiting
FOREST is a positive emotion skills program designed to target mental health and coping needs for frontline violence prevention workers at UCAN. Ten skills are taught over a period of nine months during existing meetings and wellness activities, as well as in online modules in UCAN's Learning Management System (LMS). Through infusing the FOREST skills throughout UCAN, we hope to inspire organizational culture change that will emphasize the importance of wellbeing and enhance resilience, therefor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Burnout, Burnout, Professional, Positive Affect, Depression, Anxiety, Compassion Fatigue, Job Stress
EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA
Recruiting
The purpose of this study is to investigate the safety and efficacy of the current hard gelatin capsule formulation of NRD135S.E1 80 mg once daily in the treatment of PDPN when administered for 13 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Northwestern Department of Neurology, Chicago, Illinois
Conditions: Painful Diabetic Neuropathy
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
Recruiting
This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10\^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Illinois, Chicago, Illinois
Conditions: Fecal Incontinence
Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
Recruiting
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/01/2025
Locations: Shirley Ryan Abilitylab, Chicago, Illinois
Conditions: SCI - Spinal Cord Injury
973 - 984 of 1984